ARMP•benzinga•
Armata Pharmaceuticals Announced Topline Results From Its Phase 2 Tailwind Trial Of AP-PA02 For Chronic Pulmonary Pseudomonas Aeruginosa Infections In Non-cystic Fibrosis Bronchiectasis Patients
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 19, 2024 by benzinga